Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2019-06-28 AGM Information
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Update concerning subscription undertakings in Karolinska Development’s directed share issue to the holders of the Company’s convertible loan
AGM Information Classification · 1% confidence The document is a press release from Karolinska Development AB regarding a 'directed issue of series B shares' (a capital raise/financing activity). It details subscription undertakings from investors and mentions that the resolution is subject to approval at the AGM. While it mentions an upcoming AGM, the core content is about the financing structure and capital change. According to the filing definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2019-06-28 English
Update concerning subscription undertakings in Karolinska Development’s directed share issue to the holders of the Company’s convertible loan
Capital/Financing Update Classification · 1% confidence The document is a press release dated June 28, 2019, announcing an update regarding subscription undertakings for a 'Directed share issue' which is conditional on approval at the upcoming Annual General Meeting (AGM). It discusses financing activities (convertible loan set-off for shares) and mentions the AGM approval. Since the core subject is an update on commitments related to a capital/financing event (share issue via loan conversion), the most fitting primary category is Capital/Financing Update (CAP). Although it mentions the AGM, the focus is on the financing mechanics and subscription commitments, not the AGM results or presentation materials. It is not a full 10-K, ER, or IR. It is an announcement about a financing/capital structure change.
2019-06-28 English
Karolinska Development avyttrar sitt ägande i Pharmanest för 23 mkr
Capital/Financing Update Classification · 1% confidence The document is a press release from Karolinska Development AB dated June 27, 2019, announcing the sale (avyttrar) of its entire ownership stake in a portfolio company, Pharmanest AB, for 23 million SEK. This transaction involves a change in asset holding and capital structure related to an investment. It is not a standard periodic report (10-K, IR, ER), a management change (MANG), or a director's trade (DIRS). Since the core event is the divestment of an asset which impacts the company's capital/investment portfolio, the most fitting category is Capital/Financing Update (CAP), as it details a significant capital transaction/restructuring of assets. It is also a regulatory disclosure as indicated by the final sentence referencing the EU Market Abuse Regulation (MAR). Given the options, CAP covers the nature of the transaction best, although RNS is a possibility if CAP were too narrow. However, the content is specifically about a capital event (divestment/liquidity generation), making CAP the primary fit over the general RNS fallback.
2019-06-27 Swedish
Karolinska Development sells its ownership in Pharmanest for SEK 23 million
M&A Activity Classification · 1% confidence The document announces a specific corporate transaction: the sale of the company's entire ownership in a portfolio company (Pharmanest) for a specific cash amount (SEK 23 million). This is a material event related to the company's assets and investments. It is not a full annual report (10-K), an interim report (IR), an earnings release (ER), or a management discussion (MDA). It is a specific corporate action announcement. Since there is no specific category for 'Divestiture' or 'Asset Sale', and it is a material announcement concerning the company's structure/investments, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for specific corporate actions not covered by other codes, or potentially 'Capital/Financing Update' (CAP) if the sale is viewed as a liquidity event, but RNS is safer for specific transaction news. Given the nature of the announcement (sale of an investment), it is a significant corporate event disclosure. I will classify it as RNS as it is a general regulatory disclosure of a material event not covered by other specific codes like DIV, SHA, or TAR.
2019-06-27 English
Announcement of the final terms and conditions of Karolinska Development’s directed share issue to the holders of the Company’s convertible loan
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the final terms of a 'Directed share issue' (a capital restructuring involving the conversion of debt to equity). It details the background, subscription price, and conditions of the issue, and includes a timetable for the upcoming AGM. While it mentions the AGM, it is not the AGM materials themselves, nor is it a report; it is a corporate announcement regarding financing and capital structure changes. Therefore, it falls under the 'Capital/Financing Update' category.
2019-06-26 English
Announcement of the final terms and conditions of Karolinska Development’s directed share issue to the holders of the Company’s convertible loan
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the final terms of a 'Directed share issue' (a capital restructuring involving the conversion of debt to equity). It details the background, subscription price, and conditions of the issue, and includes a timetable for the upcoming AGM. While it mentions the AGM, it is not the AGM materials themselves, nor is it a report; it is a corporate announcement regarding financing and capital structure changes. Therefore, it falls under the 'Capital/Financing Update' category.
2019-06-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.